ReliantHeart’s next-generation aVAD left ventricular assist device has just earned CE Mark approval and implants are set to begin in September.
ReliantHeart’s new left ventricular assist device (LVAD), the aVAD, has been approved for commercial implants in Europe. On Tuesday, the company received CE Mark approval for the aVAD.